UNSPSC 51334206: Clorotepine maleate

This classification denotes the maleate form of a dopamine antagonist with the molecular formula C19H21ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E65W20MU7A, chemically known as 1-(8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methylpiperazine but more generally known as clorotepine, which bears US NIH Compound Identifier 1238. European Medicines Agency schedules Clorotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06765MIG.

UNSPSC 51334206 Clorotepine maleate is a Commodity code that does not align with recent state and local procurement activity under the code's classification. The three most recent opportunities tagged to this code — Seminole County's procurement for naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and Minnesota's MMCAP RFP for generic multi-source pharmaceuticals and OTC products — involve naloxone, pharmacy benefit management, and broad pharmaceutical distribution, none of which directly concern clorotepine maleate, an atypical antipsychotic agent. State and local health agencies do procure pharmaceuticals through both direct purchase and cooperative purchasing agreements, but the specific active opportunities in the block address different pharmaceutical categories and supply-chain models than the code's nominal product specification.

The issuing bodies pursuing pharmaceutical procurement span state health departments (Texas HHS), county health systems (Seminole County, Florida), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). Recent activity shows mixed procurement methods: Seminole County issued an IFB (due July 26, 2023) for naloxone supply with quarterly deliveries; Texas HHS posted an RFI (due April 3, 2026) to gather vendor capabilities for direct manufacturer relationships; and MMCAP issued an RFP (due March 26, 2026) for generic pharmaceuticals distributed through authorized wholesalers. The code shows no recent opportunities explicitly soliciting clorotepine maleate. If this code is your target, verify with issuing bodies whether it reflects their actual procurement taxonomy or whether parallel codes capturing antipsychotic pharmaceuticals, psychiatric medications, or broad generic drug procurement would better align with current market activity.